Session Details
[JS7]ENCORE SEOUL@CVIT2025: Antiplatelet therapy: Emerging Strategies and Clinical Evidence of P2Y12 Inhibitors
Fri. Jul 18, 2025 2:10 PM - 3:40 PM JST
Fri. Jul 18, 2025 5:10 AM - 6:40 AM UTC
Fri. Jul 18, 2025 5:10 AM - 6:40 AM UTC
Room 4 (12F,OICC)
Chair：Hyeon-Cheol Gwon(Samsung Medical Center, Korea),Tetsuya Matoba(Department of Cardiovascular Medicine, Kyushu University, Japan)
Commentator：Donghoon Choi(Severance Hospital, Korea),Raisuke Iijima(Toho University Medical Center Ohashi Hospital, Japan),Gaku Nakazawa(Kindai University, Japan),Hirotoshi Watanabe(Hirakata Kohsai Hospital, Japan)
Commentator：Donghoon Choi(Severance Hospital, Korea),Raisuke Iijima(Toho University Medical Center Ohashi Hospital, Japan),Gaku Nakazawa(Kindai University, Japan),Hirotoshi Watanabe(Hirakata Kohsai Hospital, Japan)
In this session, we will focus on the management strategies and clinical evidence of antiplatelet therapy. Opinion leaders in this field will present current real-world studies. This is a joint session with ENCORE but we welcome worldwide participants for interactive discussion.
[JS7-1]Clopidogrel Versus Aspirin Monotherapy in High-Risk Patients after PCI: SMART-CHOICE 3 Trial
Joo-Yong Hahn (Division of Cardiology, Department of Medicine, Heart Vasucular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)
[JS7-2]Prasugrel Monotherapy: Insights from the STOPDAPT-3 trial
Masahiro Natsuaki ( Saga University, Japan)
[JS7-3]Optimal duration of dual antiplatelet therapy after PCI according to the bleeding risk: HOST-BR stratified and randomized study
Hyo-Soo Kim (Seoul National University Hospital, Korea)
[JS7-4]Optimizing P2Y12 Inhibition in East Asian Patients: Japan-Dose vs. Standard-Dose
Satoshi Honda (National Cerebral and Cardiovascular Center, Japan)